Insigneo Advisory Services LLC Has $268,000 Stock Holdings in CVS Health Co. (NYSE:CVS)

Insigneo Advisory Services LLC reduced its holdings in shares of CVS Health Co. (NYSE:CVS) by 24.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,980 shares of the pharmacy operator’s stock after selling 1,886 shares during the quarter. Insigneo Advisory Services LLC’s holdings in CVS Health were worth $268,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Norges Bank bought a new stake in shares of CVS Health during the 4th quarter valued at approximately $839,574,000. Davis Selected Advisers boosted its position in CVS Health by 2,998.1% in the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator’s stock valued at $511,115,000 after buying an additional 11,018,438 shares in the last quarter. Dodge & Cox grew its stake in shares of CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator’s stock worth $3,147,054,000 after buying an additional 7,075,209 shares during the last quarter. Pzena Investment Management LLC lifted its stake in shares of CVS Health by 49.3% in the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator’s stock valued at $880,319,000 after acquiring an additional 6,475,271 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of CVS Health by 30.1% during the 4th quarter. Invesco Ltd. now owns 18,038,089 shares of the pharmacy operator’s stock valued at $809,730,000 after acquiring an additional 4,173,243 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, January 30th. Mizuho lifted their target price on shares of CVS Health from $70.00 to $76.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 9th. Argus set a $77.00 price target on shares of CVS Health in a research report on Tuesday, February 18th. Wells Fargo & Company boosted their price objective on shares of CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $71.83.

Insider Buying and Selling at CVS Health

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by company insiders.

CVS Health Stock Down 2.0 %

Shares of NYSE CVS opened at $67.19 on Friday. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $71.45. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The firm has a market cap of $84.71 billion, a PE ratio of 18.36, a P/E/G ratio of 0.98 and a beta of 0.57. The company’s fifty day simple moving average is $66.46 and its 200 day simple moving average is $58.79.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, sell-side analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.96%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health’s payout ratio is currently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.